Amgen To Acquire Five Prime Therapeutics - Quick Facts

安进获得五种主要疗法-速报

2021-03-05 00:31:48 RTTNews

本文共268个字,阅读需1分钟

Amgen has agreed to acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. The acquisition includes Bemarituzumab, a phase 3 ready, first-in-class program for Gastric Cancer. Five Prime's lead asset, bemarituzumab, is a anti-FGFR2b antibody with positive data from a randomized, placebo-controlled phase 2 study in frontline advanced gastric or gastroesophageal junction cancer. Amgen reaffirmed its full-year outlook with revenue guidance of $25.8 to $26.6 billion and non-GAAP EPS guidance of $16.00-$17.00. For comments and feedback contact: editorial@rttnews.com Business News
安进已同意以每股38.00美元的现金收购五家Prime Therapeutics公司,其股权价值约为19亿美元。此次收购包括Bemarituzumab,这是一种3期准备好的、一流的胃癌治疗方案。 Five Prime的主导资产bemarituzumab是一种抗FGFR2B抗体,其阳性数据来自一项随机、安慰剂对照的前线晚期胃或胃食管交界癌2期研究。 安进重申其全年预期,营收指引为258-266亿美元,非GAAP每股收益指引为16.00-17.00美元. 如需评论和反馈,请联系:editorial@rttnews.com 商业新闻

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文